Cytokine Release Syndrome (CRS)

Recognition, grading, and management of one of the most serious toxicities of immunotherapy and cellular therapy

Key Points

• CRS is a systemic inflammatory response caused by massive immune activation — most commonly seen after CAR-T cell therapy, bispecific antibodies, and high-dose IL-2.
• Hallmark symptoms are fever (≥38°C) plus hypotension and/or hypoxia; severity is graded 1–4 by ASTCT criteria.
• Tocilizumab (IL-6 receptor antagonist) is the first-line treatment for CRS grade ≥2; corticosteroids are added for refractory or severe cases.
• Most CRS occurs within 1–14 days of CAR-T infusion; onset with bispecific antibodies is typically within 24–72 hours of each dose.
• Elevated CRP and ferritin track disease severity; ferritin >10,000 ng/mL should prompt consideration of hemophagocytic lymphohistiocytosis (HLH).
• Patients must be educated to report fever immediately — even grade 1 CRS can escalate rapidly without intervention.

What Is Cytokine Release Syndrome?

Cytokine Release Syndrome (CRS) is a systemic inflammatory response that occurs when a large number of immune cells are rapidly activated and release massive quantities of pro-inflammatory cytokines into the circulation. The primary mediators include interleukin-6 (IL-6), interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-10 (IL-10). CRS is most commonly associated with: - **CAR-T cell therapy** (chimeric antigen receptor T-cell therapy): the highest-risk setting, occurring in 50–90% of patients depending on the product and disease -…

Symptoms and Clinical Presentation

CRS typically presents as a spectrum from mild constitutional symptoms to a life-threatening systemic inflammatory syndrome. Onset with CAR-T therapy is usually 1–3 days post-infusion (median 2–3 days) and can persist for 7–14 days. With bispecific antibodies, CRS tends to occur within 24–48 hours of each dose and often diminishes with subsequent cycles once tolerance develops. **Systemic symptoms (universal in significant CRS):** - Fever ≥38°C — the sine qua non of CRS; fever is required for the diagnosis - Rigors, chills, diaphoresis - Headache, malaise, fatigue - Myalgias, arthralgias…

Grading — ASTCT Consensus Criteria

The American Society for Transplantation and Cellular Therapy (ASTCT) 2019 consensus grading criteria are now the standard for grading CRS: **Grade 1:** Fever ≥38°C; no hypotension; no hypoxia **Grade 2:** Fever ≥38°C PLUS hypotension NOT requiring vasopressors AND/OR hypoxia requiring low-flow supplemental oxygen (≤6 L/min nasal cannula) **Grade 3:** Fever ≥38°C PLUS hypotension requiring one vasopressor (with or without vasopressin) AND/OR hypoxia requiring high-flow oxygen (>6 L/min nasal cannula, face mask, or non-rebreather mask) **Grade 4:** Fever ≥38°C PLUS hypotension requiring…

Management by Grade

Management is guided by CRS grade and rate of progression. All patients receiving CAR-T therapy or bispecific antibodies require close monitoring — institutional protocols vary, but frequent vital sign assessment and laboratory monitoring (CRP, CBC, CMP, ferritin) are standard. **Grade 1:** - Supportive care: antipyretics (acetaminophen ±diphenhydramine), IV fluids if indicated - Maintain close monitoring for escalation - Continue CAR-T/bispecific therapy if clinically stable **Grade 2:** - Tocilizumab 8 mg/kg IV (max 800 mg) — first-line anti-cytokine therapy; can be repeated every 8 hours…

Patient Education and Home Monitoring

Patient and caregiver education is essential before administering CAR-T therapy or bispecific antibodies. Most severe CRS events develop during the mandatory monitoring period (typically the first 7–14 days after CAR-T infusion), but milder episodes can develop after discharge. **Instructions for patients and caregivers:** - Check temperature at least twice daily during the monitoring period - Call the oncology team immediately for any fever ≥38°C (100.4°F), regardless of how you feel otherwise - Go to the emergency department immediately for: difficulty breathing, confusion or…